Press Releases
-
Oct 6, 2020Company's highest revenue quarter to date is more than 2X its entire fiscal 2019 revenue...Oct 5, 2020Live Conference Call and Webcast at 4:30 PM ET...Sep 23, 2020ENGLEWOOD, CO / ACCESSWIRE / September 23, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that it will reschedule its fourth quarter and FY 2020 conference call, previously scheduled for Thursday, September 24 at 4:30pm ET....Sep 16, 2020Live Conference Call and Webcast at 4:30 ET...Sep 8, 2020Pinnacle Plans to Scale U.S. Manufacturing Capacity to 25 Million Tests Per Month...Aug 19, 2020Aytu BioScience COVID-19 IgG/IgM Rapid Test Distribution Partner Apollo Med Innovations Initiates Nationwide Mobile Testing Partnership with Olympus Health and Performance...Aug 17, 2020Delivery of Investigational Endotracheal Ultraviolet-A Light Catheter Devices Enables Near-Term Initiation of Planned Clinical Studies in Severely Ill COVID-19 Patients...Jul 30, 2020ENGLEWOOD, CO / ACCESSWIRE / July 30, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs, today announced the approval of ZolpiMist® (zolpidem tartrate oral spray) by the Therapeutic Goods Administration (TGA) in Australia. This approval, which was secured by the Company's ...Jul 27, 2020Article Reports Results from Independent Study Demonstrating Test's 100% Sensitivity and Specificity for IgM Antibodies and 96.7% and 97.5% Sensitivity and Specificity, Respectively, for IgG Antibodies...Jul 20, 2020Commercial Partner Acerus Pharmaceuticals Launches Specialty Sales Team Calling on Urologists and Endocrinologists in the United States ...